Announced Date: 2023-02-23 (February 23, 2023)
Asset Name: CMG901
Licensor (Seller): KYM Biosciences (China) (joint venture established by Keymed Biosciences and Lepu Biopharma)
Licensee (Buyer): AstraZeneca
.
Asset Modality: antibody drug conjugate (ADC)
Asset Target: Claudin-18.2
Current Stage: Phase I
Potential Indication: gastric cancer
.
Scope of Authority:
AstraZeneca will be responsible for the research, development, manufacture and commercialisation of CMG901 globally.
.
Payment Detail:
Upfront payment of $63m,
Development and sales-related milestone payments of up to $1.1bn.
Tiered royalties up to low double digits.
.
Link:
.
Note:
Chinese Name
Keymed Biosciences 康诺亚生物
Lepu Biopharma 乐普生物
